Zobrazeno 1 - 10
of 36
pro vyhledávání: '"Lily L Remsing Rix"'
Autor:
Uwe Rix, Jacques Colinge, Katharina Blatt, Manuela Gridling, Lily L Remsing Rix, Katja Parapatics, Sabine Cerny-Reiterer, Thomas R Burkard, Ulrich Jäger, Junia V Melo, Keiryn L Bennett, Peter Valent, Giulio Superti-Furga
Publikováno v:
PLoS ONE, Vol 8, Iss 10, p e77155 (2013)
Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) is in part driven by the tyrosine kinase bcr-abl, but imatinib does not produce long-term remission. Therefore, second-generation ABL inhibitors are currently in clinical investi
Externí odkaz:
https://doaj.org/article/71bb1f7bea894117aa5e71d83b77d809
Autor:
Bhaswati Sarcar, Nicholas T. Gimbrone, Gabriela Wright, Lily L. Remsing Rix, Edna R. Gordian, Uwe Rix, Alberto A. Chiappori, Gary W. Reuther, Pedro G. Santiago‐Cardona, Teresita Muñoz‐Antonia, William Douglas Cress
Publikováno v:
FEBS Open Bio, Vol 9, Iss 10, Pp 1689-1704 (2019)
Lung cancer patients with mutations in epidermal growth factor receptor (EGFR) benefit from treatments targeting tyrosine kinase inhibitors (TKIs). However, both intrinsic and acquired resistance of tumors to TKIs are common, and EGFR variants have b
Externí odkaz:
https://doaj.org/article/6e8351e2101b44f9952c7a2874a030c7
Autor:
Manali Phadke, Lily L. Remsing Rix, Inna Smalley, Annamarie T. Bryant, Yunting Luo, Harshani R. Lawrence, Braydon J. Schaible, Yian A. Chen, Uwe Rix, Keiran S. M. Smalley
Publikováno v:
Molecular Oncology, Vol 12, Iss 1, Pp 74-88 (2018)
Although the BRAF inhibitors dabrafenib and vemurafenib have both proven successful against BRAF‐mutant melanoma, there seem to be differences in their mechanisms of action. Here, we show that dabrafenib is more effective at inhibiting the growth o
Externí odkaz:
https://doaj.org/article/0ea6fa99919646bc91e83cc59238e18b
Autor:
Lily L. Remsing Rix, Natalia J. Sumi, Qianqian Hu, Bina Desai, Annamarie T. Bryant, Xueli Li, Eric A. Welsh, Bin Fang, Fumi Kinose, Brent M. Kuenzi, Y. Ann Chen, Scott J. Antonia, Christine M. Lovly, John M. Koomen, Eric B. Haura, Andriy Marusyk, Uwe Rix
Publikováno v:
Sci Signal
Cancer-associated fibroblasts (CAFs) in the tumor microenvironment are often linked to drug resistance. Here, we found that coculture with CAFs or culture in CAF-conditioned medium unexpectedly induced drug sensitivity in certain lung cancer cell lin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::36adee87933095a837fc80a8b792b3d6
https://doi.org/10.1126/scisignal.abj5879
https://doi.org/10.1126/scisignal.abj5879
Autor:
W D Cress, Nicholas T. Gimbrone, Alberto Chiappori, Gabriela Wright, Bhaswati Sarcar, Teresita Muñoz-Antonia, Edna Gordian, Uwe Rix, Gary W. Reuther, Pedro G. Santiago-Cardona, Lily L. Remsing Rix
Publikováno v:
FEBS Open Bio. 9:1689-1704
Lung cancer patients with mutations in epidermal growth factor receptor (EGFR) benefit from treatments targeting tyrosine kinase inhibitors (TKIs). However, both intrinsic and acquired resistance of tumors to TKIs are common, and EGFR variants have b
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::24b9674d0d90efacc7796a13a548ce11
https://doi.org/10.1002/2211-5463.12702
https://doi.org/10.1002/2211-5463.12702
Autor:
Brent M. Kuenzi, Jodi L. Kroeger, Jeffrey E. Lancet, Eric Padron, Lily L. Remsing Rix, Uwe Rix, Fumi Kinose
Publikováno v:
Scientific Reports, Vol 9, Iss 1, Pp 1-12 (2019)
Scientific Reports
Scientific Reports
GSK3α has been identified as a new target in the treatment of acute myeloid leukemia (AML). However, most GSK3 inhibitors lack specificity for GSK3α over GSK3β and other kinases. We have previously shown in lung cancer cells that GSK3α and to a l
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a18c34c87844d73251d15fb1c71ca0d4
http://link.springer.com/article/10.1038/s41598-018-37174-6
http://link.springer.com/article/10.1038/s41598-018-37174-6
Autor:
Natalia J. Sumi, Uwe Rix, John M. Koomen, Eric B. Haura, Fumi Kinose, Lily L. Remsing Rix, Victoria Izumi, Vinayak Palve, Silvia Novakova, Brent M. Kuenzi, Bin Fang, Claudia Ctortecka
Publikováno v:
Molecular & Cellular Proteomics. 17:2434-2447
Lung cancer is associated with high prevalence and mortality, and despite significant successes with targeted drugs in genomically defined subsets of lung cancer and immunotherapy, the majority of patients currently does not benefit from these therap
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ecee45c4cee449f7823495459a61de01
https://doi.org/10.1074/mcp.ra118.000713
https://doi.org/10.1074/mcp.ra118.000713
Autor:
Yunting Luo, Keiran S.M. Smalley, Braydon Schaible, Annamarie T. Bryant, Inna Smalley, Yian A. Chen, Manali Phadke, Uwe Rix, Harshani R. Lawrence, Lily L. Remsing Rix
Publikováno v:
Molecular Oncology, Vol 12, Iss 1, Pp 74-88 (2018)
Molecular Oncology
Molecular Oncology
Although the BRAF inhibitors dabrafenib and vemurafenib have both proven successful against BRAF-mutant melanoma, there seem to be differences in their mechanisms of action. Here, we show that dabrafenib is more effective at inhibiting the growth of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::42a6a065be4c93d055cb5724f5f140e2
https://doaj.org/article/0ea6fa99919646bc91e83cc59238e18b
https://doaj.org/article/0ea6fa99919646bc91e83cc59238e18b
Publikováno v:
Semin Cancer Biol
Targeted drugs and precision medicine have transformed the landscape of cancer therapy and significantly improved patient outcomes in many cases. However, as therapies are becoming more and more tailored to smaller patient populations and acquired re
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::220eec99e0f8be317cdba0111d56be3e
https://pubmed.ncbi.nlm.nih.gov/32044472
https://pubmed.ncbi.nlm.nih.gov/32044472
Autor:
Ian Pike, Eric A. Welsh, Gary W. Reuther, Lily L. Remsing Rix, Bin Fang, Uwe Rix, John M. Koomen, Eric B. Haura, Victoria Izumi
Publikováno v:
Proteomics
Analysis of tyrosine kinase signaling is critical for the development of targeted cancer therapy. Currently, immunoprecipitation of phosphotyrosine (pY) peptides prior to liquid chromatography-tandem mass spectrometry (LC-MS/MS) is used to profile ty
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c1e20177f0f3f27aca9a156fca2485c4
https://doi.org/10.1002/pmic.202000116
https://doi.org/10.1002/pmic.202000116